LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm increased the cumulative apnea-hypopnea index ...
Finanznachrichten

LivaNova PLC: LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

Presentation at SLEEP 2026 illustrates ability to convert non-responders into responders using personalized programming LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today ...

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

Detailed price information for Bioxcel Therapeutics Inc (BTAI-Q) from The Globe and Mail including charting and trades.